To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in groups 1 and 2 as well as other rapidly emerging viruses that utilize the…
Ended Awarded Last action
- Contract number
- 75N93023F00001
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $424,108
Award facts
- Contract value 77% obligated
-
- $424,108.16 Current, with exercised options
- $548,829.16 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35294, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $6,023 | |
| Original award | $418,085 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a Delivery Order contract to the University of Alabama at Birmingham (UAB) to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses. The contract is a Firm Fixed Price type awarded under the larger In Vitro Assessments of Antimicrobial Activity (IVAAA) Indefinite Delivery Contract (IDC). The contract has a ceiling value of $548,829.16 and a completion date of September 4, 2024. UAB, a non-profit educational institution, will perform the work at its facilities in Birmingham, Alabama. This contract does not have a set-aside designation.
Description
To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in groups 1 and 2 as well as other rapidly emerging viruses that utilize the same assay methodology.
Quick answers
Who was awarded contract 75N93023F00001?
75N93023F00001 was awarded to University Of Alabama At Birmingham by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 5, 2023.
How much is contract 75N93023F00001 worth?
The government has obligated $424,108 on 75N93023F00001. Its potential value, with all options, is $548,829.
Is contract 75N93023F00001 an order under another contract?
Yes. 75N93023F00001 is a delivery order under 75N93019D00016, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93023F00001 competed?
The extent of competition for 75N93023F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award